Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,620 | 0,680 | 08:04 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.08. | JW THERAP-B (02126): NOTICE OF BOARD MEETING | 1 | HKEx | ||
26.06. | JW THERAP-B (02126): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025 | - | HKEx | ||
03.06. | JW THERAP-B (02126): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 3, 2025 | 2 | HKEx | ||
28.05. | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE NMPA ACCEPTANCE OF THE SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION FOR CARTEYVA ... | - | HKEx | ||
15.05. | JW THERAP-B (02126): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON JUNE 3, 2025 | - | HKEx | ||
JW THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
15.05. | JW THERAP-B (02126): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
15.05. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO LICENSE AGREEMENT | - | HKEx | ||
14.05. | JW THERAP-B (02126): CLOSURE OF REGISTER OF MEMBERS | - | HKEx | ||
08.05. | JW THERAP-B (02126): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2025 | - | HKEx | ||
08.05. | JW THERAP-B (02126): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
08.05. | JW THERAP-B (02126): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES, TRANSFER SHARES OUT OF TREASURY AND REPURCHASE SHARES AND RE-ELECTION OF DIRECTORS ... | 3 | HKEx | ||
28.04. | JW THERAP-B (02126): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
28.04. | JW THERAP-B (02126): 2024 ANNUAL REPORT | 1 | HKEx | ||
22.04. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO THE LICENSE AGREEMENT AND FURTHER INFORMATION RELATING TO THE MATERIAL TRANSFER AGREEMENT | 2 | HKEx | ||
11.04. | JW THERAP-B (02126): GRANT OF SHARE OPTIONS | 3 | HKEx | ||
02.04. | JW THERAP-B (02126): NEXT DAY DISCLOSURE RETURN | 5 | HKEx | ||
27.03. | JW THERAP-B (02126): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
19.03. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO MATERIAL TRANSFER AGREEMENT | - | HKEx | ||
17.03. | JW THERAP-B (02126): NOTICE OF BOARD MEETING | - | HKEx | ||
14.03. | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 5 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ARCELLX | 71,77 | +0,36 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
QIAGEN | 42,580 | +0,69 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen nach einer Investorenveranstaltung auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Das Interesse der Teilnehmer... ► Artikel lesen | |
HARMONY BIOSCIENCES | 37,290 | +1,80 % | SUSANNAH CONSTANTINE, 63, CHOOSES THE NEW ALMA HARMONY BIO-BOOST FOR MID-LIFE SKIN CONFIDENCE | *The Next Generation Collagen Laser Facial for glowing, smoother, firmer skin*
The author, podcaster and TV personality Susannah Constantine, 63, opens up about confidence, ageing, and... ► Artikel lesen | |
KYMERA THERAPEUTICS | 42,590 | +0,54 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen | |
EVOTEC | 6,116 | +0,59 % | Evotec-Aktie: Neue Tiefs in Sicht? Nur ein Wunder kann jetzt wohl noch helfen! | © Foto: Foto von Anna Shvets auf PexelsDie Hamburger Biotechfirma Evotec kämpft ums Überleben. Das traditionelle Geschäft mit der Wirkstoffforschung bricht weg, während die hochgelobte Biologics-Sparte... ► Artikel lesen | |
THARIMMUNE | 4,970 | 0,00 % | Tharimmune Inc.: Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments | RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 56,56 | +2,08 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
JANUX THERAPEUTICS | 24,000 | -3,50 % | Piper Sandler nimmt Coverage für Janux Therapeutics mit "Overweight"-Rating auf | ||
BIONTECH | 95,10 | +0,79 % | CureVac vor Übernahme durch BioNTech: Geringerer Verlust im ersten Halbjahr | CureVac hat im zweiten Quartal 2025 einen Umsatz von 1,2 Millionen Euro erzielt, nach 14,4 Millionen Euro im Vorjahreszeitraum. Der operative Verlust verringerte sich auf 61,7 Millionen Euro, nach 73... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 14,610 | -5,62 % | Jefferies belässt Mineralys auf 'Hold' und blickt auf entscheidende Daten von AstraZeneca | ||
RECURSION PHARMACEUTICALS | 4,765 | 0,00 % | Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares | ||
VIKING THERAPEUTICS | 22,085 | -0,09 % | Viking Therapeutics-Aktie: +50% nach Kauftipp Anfang Juli! | Nächster Volltreffer unserer Biotech-Profis: Anfang Juli haben wir auf die großen Kurschancen bei der Aktie von Viking Therapeutics aufmerksam gemacht. Inzwischen notiert das Papier rund +50% höher... ► Artikel lesen | |
VERA THERAPEUTICS | 22,605 | +2,29 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,640 | +0,68 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
TEMPUS AI | 66,50 | 0,00 % | Tempus AI: KI-Aktie wie entfesselt nach Zahlen | Der KI-Spezialist Tempus AI hat vor wenigen Handelstagen einen überzeugenden Bericht zum zweiten Quartal vorgelegt. Seitdem kennt die Aktie des Unternehmens, welches erst vor rund zehn Jahren in Chicago... ► Artikel lesen |